Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Florence Joly1, Denis Querleu2, Moise Namer3

  • 1Département d'oncologie médicale, centre François-Baclesse, 14000 Caen, France.

Bulletin Du Cancer
|June 20, 2017
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to Yu, Wang and Ge.

Journal of the National Cancer Institute·2026
Same author

Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial.

Translational oncology·2026
Same author

In-transit lymph node metastases in the ovarian pedicle in early-stage ovarian cancer: myth or reality?

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

Adjuvant Chemotherapy and Survival After Pelvic Exenteration for Gynecologic Cancers in the COREPEX Study.

JAMA network open·2026
Same author

Treatment-aware deep learning enables counterfactual prediction of individual benefit from PARP inhibitors in ovarian cancer.

NPJ digital medicine·2026
Same author

Deep learning-based prediction of homologous recombination deficiency from histopathological whole-slide images in ovarian cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same journal

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
Same journal

[Reirradiation: A new therapeutic paradigm in oncology].

Bulletin du cancer·2026
See all related articles

Updated clinical practice recommendations for ovarian and advanced cervical cancers incorporate new histological subtypes, surgical criteria, and treatments like PARP inhibitors and bevacizumab therapy for improved patient management.

Area of Science:

  • Gynecologic Oncology
  • Clinical Practice Guidelines
  • Medical Oncology

Background:

  • Management of ovarian cancer has evolved with refined histological subtypes and surgical criteria.
  • New medical treatments, including PARP inhibitors, necessitate updated ovarian cancer management protocols.
  • Advanced cervical cancer treatment now includes bevacizumab therapy, requiring guideline revisions.

Purpose of the Study:

  • To update the 2012-2013 Clinical Practice Recommendations Nice-Saint-Paul for gynecological cancers.
  • To integrate recent advancements in ovarian and advanced cervical cancer treatment into clinical guidelines.
  • To provide the medical community with current best practices for managing these cancers.

Main Methods:

  • Review and synthesis of the latest evidence and treatment options for ovarian and advanced cervical cancers.
Keywords:
Advanced Cervical cancerCancer avancé du col de l’utérusCancer de l’ovaireGuidelinesOvarian cancerRéférentiels

Related Experiment Videos

  • Incorporation of updated classifications, quality criteria for surgery, and oncogenetic research.
  • Development of revised guidelines by the GINECO group.

    • Main Results:

    • Updated recommendations for ovarian epithelial cancer (excluding rare tumors) and advanced cervical cancer.
    • Inclusion of early systematic oncogenetic research for homologous recombination pathway deficiency in ovarian cancer.
    • Integration of PARP inhibitors and bevacizumab therapy into treatment strategies.

    Conclusions:

    • The updated guidelines reflect the increasing complexity and advancements in gynecological cancer care.
    • These revised recommendations aim to standardize and improve the daily clinical practice for ovarian and advanced cervical cancer patients.
    • Rapid dissemination of these updates facilitates the adoption of the latest therapeutic strategies.